The Colossal Foundation Partners with Yellowstone Forever and the Yellowstone Wolf Project To Revolutionize Wolf Conservation Through Advanced Acoustic Monitoring Technologies
DALLAS--(BUSINESS WIRE)-- The Colossal Foundation, the 501(c)(3) nonprofit arm of Colossal Biosciences, today announced a strategic partnership with Yellowstone Forever, the official nonprofit partner of Yellowstone National Park, to support Yellowstone National Park's Wolf Project and its innovative bioacoustics efforts. The new collaboration aims to transform the way conservationists monitor and protect wild wolf populations by integrating advanced acoustic monitoring technologies, machine learning pipelines, and continuous ecological data collection.
The project will focus initially on the wolf population in Yellowstone National Park. By deploying next-generation integrated acoustic and video camera traps, the project will collect around-the-clock bioacoustics data from wolves and other wildlife in Yellowstone that share wolf pack territories. These recordings will be analyzed by a sophisticated, modular software pipeline developed by the Colossal Foundation's artificial intelligence team, which uses machine-learning algorithms to parse massive vocalization datasets—an approach that can be replicated for multiple species inside Yellowstone and beyond.
The custom-built models will automatically identify individual howls, chorus howls, and even gunshots, cluster calls by acoustic 'fingerprint,' and extract key metrics—such as pack identity, size, and even pup presence—allowing for non-invasive census, movement, and behavior studies. In time, the software will be able to provide deeper insights into wolf communication and social dynamics, all while employing innovative monitoring methods that minimize human impact.
"Wolves play a crucial role in maintaining the ecological balance of the Greater Yellowstone Ecosystem, yet they face significant risks from human activities," said Matt James, Executive Director of the Colossal Foundation. 'Our support of this project combines mission-critical conservation needs, such as remote monitoring and deterrence of wildlife conflict, with Colossal's strength in frontier technologies. With this fusion, we can create a blueprint for AI-driven wildlife protection worldwide.'
As of January 2024, there were at least 100 wolves in Yellowstone National Park across numerous packs and many breeding pairs. Acoustic monitoring will let researchers track population trends, pack membership changes, territory use, and responses to environmental or human disturbances with minimal intrusion, fostering better coexistence between wolves and local communities.
'Yellowstone Forever is grateful to receive support from the Colossal Foundation to further the groundbreaking work of the Yellowstone Wolf Project and expand the bioacoustic monitoring of Yellowstone's wolves,' said Sam Barkley, Chief Development Officer for Yellowstone Forever.
Over the past year, a team of hardware and software engineers at Grizzly Systems Inc. has been developing advanced solutions like the GrizCam, which integrates long-lasting camera traps with built-in acoustic recorders. Their contributions have significantly advanced the project's capacity to collect high-quality data suitable for comprehensive biological research. Jeffrey Reed, CEO of Grizzly Systems, Inc., said: 'The mission of Grizzly Systems, Inc. is to advance field science, combat wildlife crime, deter livestock depredations, and build the digital wild, sparking curiosity, education and advocacy for the next generation of tech-savvy conservationists. AI is used to sort through this data at a fraction of the cost it would take to sort through manually. Together with Colossal and the biologists at the park, we're deciphering the secrets of wolf communication. Nowhere else in the world is able to decode wolf 'language' like this.'
The Colossal Foundation's support of the Wolf Project's bioacoustics effort has led to the procurement of 25 additional GrizCam units that are to be deployed within the Greater Yellowstone Ecosystem. Data capture and recording will begin immediately upon deployment. Early successes in the project include the creation of a wolf-classifier, trained on a few-shot classifier previously developed by Colossal's AI core, that can identify individual and chorus howls with over 92% accuracy.
The Colossal Foundation is also seeking to expand the impact of this technology beyond Yellowstone's borders. Working alongside the Nez Perce Tribe—long-time leaders in wolf management across Idaho—the project will deploy a pilot network of GrizCam units on tribal lands. By pairing technical training and data analysis support with the Tribe's on-the-ground expertise and traditional ecological knowledge, the coalition will build local capacity for non-invasive wolf monitoring while honoring tribal sovereignty and deep cultural ties to the species.
'For the Nez Perce people, the wolf, or hîmiin, is more than a keystone species—it is a relative that is woven into our culture and our obligations as caretakers,' said Eric Kash, Director of the Nez Perce Tribe's Wildlife Division. 'Integrating bioacoustics technology with our on-the-ground expertise will sharpen our ability to track packs and share data across tribal and federal boundaries. Partnerships like this ensure that modern science and Indigenous knowledge move forward together for the benefit of wolves and the ecosystems they sustain.'
'We invest our time and expertise on projects that we believe will have a big impact for local stakeholders and in time, the whole of conservation,' said CEO and co-founder of Colossal Biosciences Ben Lamm. 'By merging AI, bioacoustics, and rugged field hardware, we're addressing some of the major challenges afflicting conservation and creating a scalable framework that can support coexistence wherever wolves roam.'
ABOUT THE COLOSSAL FOUNDATION
The Colossal Foundation is a 501(c)(3) dedicated to supporting the use of cutting-edge technologies to conservation efforts globally to help prevent extinction of keystone species. The organization deploys cutting-edge de-extinction technologies and support to empower partners in the field to reverse the extinction crisis.
www.ColossalFoundation.org
ABOUT YELLOWSTONE FOREVER
Yellowstone Forever is the official nonprofit partner of Yellowstone National Park, with the mission to protect, preserve and enhance the park through education and philanthropy.
www.Yellowstone.org
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
GE HealthCare drives innovation in theranostics with latest technological advances
CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.
Business Wire
15 hours ago
- Business Wire
EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
15 hours ago
- Business Wire
COUCHBASE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Couchbase, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Couchbase, Inc. (NasdaqGS: BASE) to Haveli Investments. Under the terms of the proposed transaction, shareholders of Couchbase will receive $24.50 in cash for each share of Couchbase that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
